# Capricor Therapeutics, Inc. (CAPR)

> Source: Nexqual · https://nexqual.com/CAPR · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Capricor Therapeutics, Inc. (CAPR), nexqual.com/CAPR" · informational, not investment advice.

**Price:** USD 6.13 (+4.25% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 5.88 · day 5.8–6.35 · 52w 2.96–40.37 · market cap $356M · NMS

## Key facts
- Insider open-market sales, last ~7 months: 6 Form 4 filings, $3.1M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.50 on a 1–5 scale) (10 analysts), mean target USD 27 (range 7–54).
- Total return with dividends: 1Y +0.0% vs S&P 500 +14.9%; 5Y +60.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-10, EPS estimate USD -0.41, revenue estimate $10.4M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $245K | $2.6M | $25.2M | $22.3M | $0K | — |
| Operating income | -$20.9M | -$29.7M | -$24.1M | -$42.6M | -$108M | -$135M |
| Net income | -$20.0M | -$29.0M | -$22.3M | -$40.5M | -$105M | -$129M |
| EPS (diluted) | -$0.87 | -$1.18 | -$0.83 | -$1.15 | -$2.26 | — |
| Free cash flow | -$18.0M | $2.9M | -$26.9M | -$41.2M | -$72.7M | -$115M |
| Operating margin | -8549.9% | -1163.9% | -95.6% | -191.1% | — | — |
| Net margin | -8175.9% | -1137.4% | -88.5% | -181.7% | — | — |
| Revenue growth | -21.1% | +941.8% | +886.8% | -11.5% | -100.0% | — |
| Cash + short-term investments | $34.9M | $41.4M | $39.5M | $152M | $318M | — |
| Total debt | $0K | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 1.4x · FCF yield -32.24% · Earnings yield -36.31%

## Insider sales (SEC Form 4, open-market, last ~7 months)
6 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-25 | Krasney Karen | EVP, GENERAL COUNSEL | 24,100 | $732K | 44.1% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-25 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | 24,100 | $732K | 68.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-22…2026-06-24 | Krasney Karen | EVP, GENERAL COUNSEL | 900 | $27K | 2.9% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-22…2026-06-24 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | 900 | $27K | 7.4% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-01 | Krasney Karen | EVP, GENERAL COUNSEL | 25,000 | $793K | 45% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-01 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | 25,000 | $793K | 75.2% | Yes | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Hold (mean 2.50 on a 1–5 scale), 10 analysts; mean target USD 27 (low 7, high 54).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-14 | B. Riley Securities | Upgrade | Neutral → Buy | $5 → $21 |
| 2026-09-01 | Piper Sandler | Upgrade | Neutral → Overweight | $2 → $25 |
| 2026-08-14 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | $3.5 → $28 |
| 2026-07-31 | Jones Trading | Downgrade | Buy → Hold |  |
| 2026-07-30 | Piper Sandler | Downgrade | Overweight → Neutral | $58 → $2 |
| 2026-07-30 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | $62 → $3.5 |
| 2026-07-30 | HC Wainwright & Co. | Downgrade | Buy → Neutral |  |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +0.0% | +60.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +0.0% | +9.9% |
| Volatility (annualized) | 217.2% | 143.8% |
| Max drawdown | -89.1% (Apr 2026→Jul 2026) | -89.1% (Apr 2026→Jul 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/CAPR · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in CAPR's own 10-K filed 2026-03-17 (https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Nippon Shinyaku | "These sources include our collaboration with Nippon Shinyaku Co., Ltd. ("Nippon Shinyaku"), as well as funding from organizations such as the National Institutes of Health and the California Institute for Regenerative Me…" |
| Partner | THERMO FISHER SCIENTIFIC INC. (TMO) | "On March 7, 2022, Capricor entered into a non-exclusive cell line license agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific, Inc., for the supply of certain cells which we are utilizi…" |
| Partner | San Diego | "Commencing March 13, 2024, we entered into a License and Services Agreement with Azzur Cleanrooms-on-Demand – San Diego, LLC (the "Azzur License Agreement") pursuant to which we were granted an exclusive license to use c…" |

## Company outlook (8-K filed 2026-08-13)

- "This outlook excludes any potential revenue from product sales, the potential monetization of a Priority Review Voucher, if received, or other non-operating sources of capital."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.41 | $0.35 | -218.3% | $10.4M | 8 |
| Next quarter (ends 2026-12-31) | $-0.08 | $0.57 | -114.4% | $27.9M | 8 |
| Current fiscal year (ends 2026-12-31) | $-1.45 | $-0.22 | +553.5% | $55.7M | 9 |
| Next fiscal year (ends 2027-12-31) | $-1.45 | $-0.64 | +126.0% | $56.5M | 9 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-13 (includes earnings 2026-11-10): ±38.1%; last 8 reports averaged ±15.3%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-10-30 | 7 | 157.1% | ±20.5% |
| 2026-11-06 | 14 | 168.5% | ±24.1% |
| 2026-11-13 | 21 | 157.1% | ±38.1% |
| 2026-11-20 | 28 | 315.8% | ±67.9% |
| 2026-11-27 | 35 | 446.2% | ±101.9% |
| 2026-12-04 | 42 | 339.5% | ±99.8% |
| 2026-12-18 | 56 | 362.1% | ±103.5% |
| 2027-01-15 | 84 | 323.6% | ±110.9% |